Dashboard
Manage Tickers

HRMYHarmony Biosciences Holding...

Nasdaq harmonybiosciences.com


$ 35.99 $ 0.23 (0.64 %)    

Friday, 30-Aug-2024 15:59:42 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.00 $ 5.61 (1.19 %)
DIA $ 416.44 $ 2.30 (0.56 %)
SPY $ 563.62 $ 5.33 (0.95 %)
TLT $ 96.60 $ -1.04 (-1.07 %)
GLD $ 231.30 $ -1.66 (-0.71 %)
$ 35.98
$ 33.60 x 100
-- x --
-- - --
$ 18.61 - $ 39.27
169,047
na
2.04B
$ 0.75
$ 17.74
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 04-30-2024 03-31-2024 10-Q
3 02-22-2024 12-31-2023 10-K
4 10-31-2023 09-30-2023 10-Q
5 08-01-2023 06-30-2023 10-Q
6 05-02-2023 03-31-2023 10-Q
7 02-21-2023 12-31-2022 10-K
8 11-01-2022 09-30-2022 10-Q
9 08-02-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
08/08/2024 10:57:47

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

analyst-expectations-for-harmony-biosciencess-future
Analyst Expectations For Harmony Bioscienc...
08/06/2024 20:00:57

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
08/06/2024 18:09:24

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

harmony-biosciences-says-on-track-to-submit-supplemental-new-drug-application-for-pitolisant-in-idiopathic-hypersomnia-in-q4-2024
Harmony Biosciences Says On Track To Submi...
08/06/2024 11:58:15

harmony-biosciences-reiterates-2024-net-product-revenue-guidance-of-700m---720m-est-710288m
Harmony Biosciences Reiterates 2024 Net Pr...
08/06/2024 11:57:31

As of June 30, 2024, Harmony had cash, cash equivalents and investments of $434.1 million, compared to $425.6 million as of Dec...

harmony-biosciences-q2-2024-adj-eps-105-beats-006-estimate-sales-172814m-miss-173098m-estimate
Harmony Biosciences Q2 2024 Adj. EPS $1.05...
08/06/2024 11:46:16

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $...

fda-confirms-favorable-benefit-risk-profile-of-wakix-harmony-biosciences-plans-to-launch-at-least-one-new-product-or-indication-annually-over-next-five-years-denial-of-citizen-petition-confirms-wakixs-safety-and-efficacy-for-eds-and-cataplexy-in-adults-with-narcolepsy
FDA Confirms Favorable Benefit-Risk Profil...
06/25/2024 12:07:04

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
06/25/2024 09:30:27

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

needham-reiterates-buy-on-harmony-biosciences-maintains-52-price-target
Needham Reiterates Buy on Harmony Bioscien...
06/24/2024 17:01:55

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

harmony-biosciences-announces-fda-approval-of-supplemental-new-drug-application-for-wakix
Harmony Biosciences Announces FDA Approval...
06/24/2024 11:05:13

a-glimpse-into-the-expert-outlook-on-harmony-biosciences-through-7-analysts
A Glimpse Into The Expert Outlook On Harmo...
06/21/2024 17:00:34

citigroup-initiates-coverage-on-harmony-biosciences-with-buy-rating-announces-price-target-of-48
Citigroup Initiates Coverage On Harmony Bi...
06/21/2024 14:27:05

Citigroup analyst David Hoang initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price ...

harmony-biosciences-reports-data-for-pitolisant-in-the-treatment-of-excessive-daytime-sleepiness-and-fatigue-in-myotonic-dystrophy-type-1-the-primary-efficacy-endpoint-was-the-change-from-baseline-to-week-11-in-daytime-sleepiness-scale-score-secondary-efficacy-endpoints-was-also-greater-for-pitolisant-versus-placebo
Harmony Biosciences Reports Data For Pitol...
06/05/2024 12:26:09

Harmony Biosciences (NASDAQ:HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excess...

needham-maintains-buy-on-harmony-biosciences-raises-price-target-to-52
Needham Maintains Buy on Harmony Bioscienc...
05/01/2024 09:34:56

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $50 to $52.

harmony-biosciences-expands-it-cns-focused-pipeline-with-epilepsy-candidate-q1-earnings-beat-street-view
Harmony Biosciences Expands It CNS-Focused...
04/30/2024 15:44:54

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epil...

key-takeaways-from-harmony-biosciences-analyst-ratings
Key Takeaways From Harmony Biosciences Ana...
04/30/2024 13:00:33

needham-reiterates-buy-on-harmony-biosciences-maintains-50-price-target
Needham Reiterates Buy on Harmony Bioscien...
04/30/2024 12:16:48

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $50 price target.

harmony-biosciences-acquires-epygenix-therapeutics-for-35m-with-development-milestone-payments-of-130m-and-there-is-potential-sales-milestone-payments-of-515m
Harmony Biosciences Acquires Epygenix Ther...
04/30/2024 11:14:30

Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational Trial f...

harmony-biosciences-q1-2024-adj-eps-088-beats-062-estimate-sales-154615m-miss-154796m-estimate
Harmony Biosciences Q1 2024 Adj EPS $0.88 ...
04/30/2024 11:08:24

Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $...

cantor-fitzgerald-reiterates-overweight-on-harmony-biosciences-maintains-49-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/12/2024 13:53:12

Cantor Fitzgerald analyst Charles Duncan reiterates Harmony Biosciences (NASDAQ:HRMY) with a Overweight and maintains $49 pr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION